$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

$nmtc Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000121390022081897 Filed on December 22, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022
Revenue	$114.6K	$2.011M	$171.2K
YoY Change	185.59%	3672.82%	-29.55%
Cost Of Revenue	$126.9K	$83.85K	$242.0K
YoY Change	170.89%	28.07%	-12.3%
Gross Profit	-$12.31K	$1.927M	-$70.79K
YoY Change	83.14%	-15950.66%	114.92%
Gross Profit Margin	-10.74%	95.83%	-41.36%
Selling, General & Admin	$1.664M	$1.889M	$6.979M
YoY Change	-4.5%	16.37%	11.49%
% of Gross Profit		98.03%
Research & Development	$1.563M	$1.438M	$4.929M
YoY Change	47.44%	42.64%	25.59%
% of Gross Profit		74.62%
Depreciation & Amortization	$35.89K	$33.42K	$118.6K
YoY Change	42.64%	49.46%	46.9%
% of Gross Profit		1.73%
Operating Expenses	$3.227M	$3.328M	$11.91M
YoY Change	15.15%	26.43%	16.92%
Operating Profit	-$1.784M	-$1.400M	-$10.03M
YoY Change	-36.48%	-47.05%	-1.83%
Interest Expense		$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$51.58K	$25.85K	$31.15K
YoY Change	2688.11%	2592.71%	-88.51%
Pretax Income	-$1.733M	-$1.374M	-$10.00M
YoY Change	-38.28%	-48.0%
Income Tax
% Of Pretax Income
Net Earnings	-$1.733M	-$1.374M	-$10.00M
YoY Change	-38.28%	-48.0%	0.52%
Net Earnings / Revenue	-1512.29%	-68.33%	-5841.95%
Basic Earnings Per Share	-$0.11		-$0.63
Diluted Earnings Per Share	-$0.11	-$84.78K	-$0.63
COMMON SHARES
Basic Shares Outstanding	16.24M shares	16.21M shares	16.00M shares
Diluted Shares Outstanding	16.23M shares		16.00M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.643M	$11.14M	$11.14M
YoY Change	-52.78%	61.44%	61.44%
Cash & Equivalents	$4.667M	$8.160M
Short-Term Investments	$2.975M	$2.981M	$2.981M
Other Short-Term Assets	$325.5K	$296.7K	$296.7K
YoY Change	136.79%	21.56%	21.56%
Inventory	$903.6K	$704.5K	$704.5K
Prepaid Expenses	$325.5K	$296.6K
Receivables	$95.32K	$33.24K	$33.24K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.967M	$12.18M	$12.18M
YoY Change	-45.9%	66.97%	66.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$334.8K	$353.6K	$535.0K
YoY Change	-30.15%	58.33%	4.43%
Goodwill
YoY Change
Intangibles	$106.3K	$111.9K
YoY Change		-16.63%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$693.2K	$646.8K	$646.9K
YoY Change	14.03%	0.06%	0.06%
TOTAL ASSETS
Total Short-Term Assets	$8.967M	$12.18M	$12.18M
Total Long-Term Assets	$693.2K	$646.8K	$646.9K
Total Assets	$9.660M	$12.82M	$12.82M
YoY Change	-43.78%	61.52%	61.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$861.6K	$927.7K	$927.7K
YoY Change	22.44%	75.42%	75.42%
Accrued Expenses	$473.1K	$715.8K	$715.8K
YoY Change	32.75%	11.11%	11.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.335M	$3.099M	$3.099M
YoY Change	25.64%	162.22%	162.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$153.7K	$119.6K	$119.6K
YoY Change	-11.3%	-41.07%	-41.07%
Total Long-Term Liabilities	$153.7K	$119.6K	$119.6K
YoY Change	-11.3%	-41.07%	-41.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.335M	$3.099M	$3.099M
Total Long-Term Liabilities	$153.7K	$119.6K	$119.6K
Total Liabilities	$1.488M	$3.218M	$3.218M
YoY Change	20.46%	132.43%	132.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$52.56M	-$50.83M
YoY Change		24.49%
Common Stock	$16.24K	$16.22K
YoY Change		35.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.172M	$9.604M	$9.604M
YoY Change
Total Liabilities & Shareholders Equity	$9.660M	$12.82M	$12.82M
YoY Change	-43.78%	61.52%	61.52%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022
OPERATING ACTIVITIES
Net Income	-$1.733M	-$1.374M	-$10.00M
YoY Change	-38.28%	-48.0%	0.52%
Depreciation, Depletion And Amortization	$35.89K	$33.42K	$118.6K
YoY Change	42.64%	49.46%	46.9%
Cash From Operating Activities	-$3.492M	$1.018M	-$7.520M
YoY Change	30.35%	-150.16%	-12.59%
INVESTING ACTIVITIES
Capital Expenditures	$11.51K	-$66.19K	$275.2K
YoY Change	-118.72%	88.52%	-510.3%
Acquisitions
YoY Change
Other Investing Activities	$26.58K	-$2.970M	-$2.970M
YoY Change
Cash From Investing Activities	$15.07K	-$3.036M	-$3.245M
YoY Change	-124.51%	8546.34%	4737.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$15.71K	0.000	$12.02M
YoY Change	-100.13%	-100.0%	4.23%
NET CHANGE
Cash From Operating Activities	-$3.492M	1.018M	-$7.520M
Cash From Investing Activities	$15.07K	-3.036M	-$3.245M
Cash From Financing Activities	-$15.71K	0.000	$12.02M
Net Change In Cash	-$3.493M	-2.018M	$1.259M
YoY Change	-137.63%	-3.42%	-56.06%
FREE CASH FLOW
Cash From Operating Activities	-$3.492M	$1.018M	-$7.520M
Capital Expenditures	$11.51K	-$66.19K	$275.2K
Free Cash Flow	-$3.504M	$1.084M	-$7.795M
YoY Change	33.85%	-154.36%	-8.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Public Float EntityPublicFloat	17000000	usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2022	nmtc	Net Valuation Change Of Instruments Measured At Fair Value NetValuationChangeOfInstrumentsMeasuredAtFairValue		usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2021	nmtc	Issuance Of Common Stock Upon Vesting Of Restricted Stock Units IssuanceOfCommonStockUponVestingOfRestrictedStockUnits		usd
CY2022	nmtc	Payroll Protection Program Loan Forgiveness PayrollProtectionProgramLoanForgiveness		usd
CY2022	nmtc	Fair Value Change Of Convertible Notes FairValueChangeOfConvertibleNotes		usd
CY2022	nmtc	Issuance Costs Attributed To Financing Activities IssuanceCostsAttributedToFinancingActivities		usd
CY2021	nmtc	Issuance Of Warrants In Connection With Zimmer Contract Amendment IssuanceOfWarrantsInConnectionWithZimmerContractAmendment		usd
CY2022	nmtc	Unpaid Purchases Of Property And Equipment UnpaidPurchasesOfPropertyAndEquipment		usd
CY2021	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering		usd
CY2022Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain		usd
CY2021Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2022	nmtc	Operating Leases OperatingLeases		usd
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40439
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-0863354
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	7599 Anagram Dr.
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	NMTC
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16238464	shares
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2022	dei	Auditor Location AuditorLocation	Minneapolis, Minnesota
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8160329	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6901346	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	2981010	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33237	usd
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48336	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	704538	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	98287	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	296649	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	244043	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	12175763	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	7292012	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	134207	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	288948	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353599	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	223329	usd
CY2022Q3	us-gaap	Assets Assets	12822609	usd
CY2021Q3	us-gaap	Assets Assets	7938496	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	927662	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	528829	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	715839	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	644249	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2021Q3	us-gaap	Deferred Revenue DeferredRevenue	8622	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3098689	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1181700	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119556	usd
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	202895	usd
CY2022Q3	us-gaap	Liabilities Liabilities	3218245	usd
CY2021Q3	us-gaap	Liabilities Liabilities	1384595	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16216540	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16216540	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12010019	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12010019	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	16217	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	12010	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60414959	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47369090	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50826812	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40827199	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	6553901	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12822609	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7938496	usd
CY2022	us-gaap	Revenues Revenues	171169	usd
CY2021	us-gaap	Revenues Revenues	178146	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	241963	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	275895	usd
CY2022	us-gaap	Gross Profit GrossProfit	-70794	usd
CY2021	us-gaap	Gross Profit GrossProfit	-97749	usd
CY2022	nmtc	Revenue From Collaboration RevenueFromCollaboration	1948872	usd
CY2021	nmtc	Revenue From Collaboration RevenueFromCollaboration	64812	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6979416	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6260266	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4929427	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3925008	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11908843	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	10185274	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10030765	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-10218211	usd
CY2021	us-gaap	Interest Expense InterestExpense	3053	usd
CY2021	nmtc	Net Valuation Change Of Instruments Measured At Fair Value NetValuationChangeOfInstrumentsMeasuredAtFairValue	1974	usd
CY2022	us-gaap	Other Income OtherIncome	31152	usd
CY2021	us-gaap	Other Income OtherIncome	271122	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9999613	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9948168	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15998567	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10696799	shares
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	2066172	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	12500000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1005232	usd
CY2021	nmtc	Issuance Costs In Connection With Private Placement IssuanceCostsInConnectionWithPrivatePlacement	-1198080	usd
CY2021	nmtc	Issuance Cost Settlement In Connection With Private Placement IssuanceCostSettlementInConnectionWithPrivatePlacement	50400	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1793199	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10146	usd
CY2021	nmtc	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	275000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9948168	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	6553901	usd
CY2022	nmtc	Issuance Of Warrants In Connections With Convertible Notes Offering IssuanceOfWarrantsInConnectionsWithConvertibleNotesOffering	13350582	usd
CY2022	nmtc	Stock Issued During Period Issuance Cost In Connection With Public Offering StockIssuedDuringPeriodIssuanceCostInConnectionWithPublicOffering	-1352280	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	104562	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	947212	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9999613	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9604364	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9999613	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9948168	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	118620	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	80748	usd
CY2022	nmtc	Allocated Share Based Compensation AllocatedShareBasedCompensation	947212	usd
CY2021	nmtc	Allocated Share Based Compensation AllocatedShareBasedCompensation	1793199	usd
CY2021	nmtc	Payroll Protection Program Loan Forgiveness PayrollProtectionProgramLoanForgiveness	83333	usd
CY2021	nmtc	Fair Value Change Of Convertible Notes FairValueChangeOfConvertibleNotes	-1974	usd
CY2021	nmtc	Issuance Costs Attributed To Financing Activities IssuanceCostsAttributedToFinancingActivities	3053	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11471	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-107593	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-66382	usd
CY2022	nmtc	Issuance Of Warrants In Connection With Zimmer Contract Amendment IssuanceOfWarrantsInConnectionWithZimmerContractAmendment	104562	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15099	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48336	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	606251	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	98287	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	145540	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8320	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	515438	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-350313	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1434817	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7477	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7519534	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8602826	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	3469539	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	500000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	275226	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67079	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3244765	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67079	usd
CY2022	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement	13350582	usd
CY2021	nmtc	Proceeds From Issuance Of Common Stock In Connection With Private Placement ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacement	8829236	usd
CY2021	nmtc	Proceeds From Issuance Of Warrants In Connection With Private Placement ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement	3670764	usd
CY2021	nmtc	Issuance Costs In Connection With Convertible Promissory Notes IssuanceCostsInConnectionWithConvertiblePromissoryNotes	3053	usd
CY2022	nmtc	Issuance Costs In Connection With Private Placements IssuanceCostsInConnectionWithPrivatePlacements	1327300	usd
CY2021	nmtc	Issuance Costs In Connection With Private Placements IssuanceCostsInConnectionWithPrivatePlacements	1198080	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	275000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10146	usd
CY2021	nmtc	Deferreds Offering Costs DeferredsOfferingCosts	-49159	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12023282	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11534854	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1258983	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2864949	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6901346	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4036397	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8160329	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6901346	usd
CY2021	nmtc	Conversion Of Convertible Promissory Notes To Equity ConversionOfConvertiblePromissoryNotesToEquity	1005232	usd
CY2021	nmtc	Broker Warrants Issued In Connection With Convertible Notes BrokerWarrantsIssuedInConnectionWithConvertibleNotes	50400	usd
CY2021	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease	73118	usd
CY2021	nmtc	Value Of Payroll Protection Program Loan Forgiveness ValueOfPayrollProtectionProgramLoanForgiveness	83333	usd
CY2021	nmtc	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts	67954	usd
CY2021	nmtc	Unpaid Purchases Of Property And Equipment UnpaidPurchasesOfPropertyAndEquipment	48651	usd
CY2022	nmtc	Reclass Of Deferred Offering Costs To Additional Paidin Capital In Connection With Public Offering ReclassOfDeferredOfferingCostsToAdditionalPaidinCapitalInConnectionWithPublicOffering	24980	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - Organization and Nature of Operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”), a Delaware corporation, is an early-stage medical technology company developing comprehensive neuromodulation electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its Evo cortical technology in November 2019 and in October 2022, we received FDA 510(k) clearance for our Evo sEEG electrode technology for temporary (less than 30 days) use <span>with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.</span> To date, the Company has had limited commercial sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is based in Eden Prairie, Minnesota.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Global Economic Conditions</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, worldwide economic conditions remain uncertain, particularly due to the effects of the COVID-19 pandemic and increased inflation. The general economic and capital market conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company’s access to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, the Company’s future cost of equity or debt capital and access to the capital markets could be adversely affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The COVID-19 pandemic that began in late 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse effect on the financial markets. Additionally, the Company’s operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflict in Ukraine, and steps taken by governments and central banks, particularly in response to the COVID-19 pandemic as well as other stimulus and spending programs, have led to higher inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including increased interest rates.</p>
CY2022Q3	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	50800000	usd
CY2022	nmtc	Unpaid Deferred Offering Costs UnpaidDeferredOfferingCosts		usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2021Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-three
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management’s Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, primarily in connection with the convertible promissory notes when outstanding, and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
CY2020Q3	nmtc	Royalty Minimum Payments Year One RoyaltyMinimumPaymentsYearOne	50000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with an original contractual maturity on date of purchase of less than or equal to three months to be classified and presented as cash equivalents on the Balance Sheets. Cash equivalents are stated at cost, which approximates fair value. The Company’s cash and cash equivalents may include demand deposit accounts with large financial institutions, institutional money market funds, U.S. treasury securities, and corporate notes and bonds. The Company monitors the creditworthiness of the financial institutions, institutional money market funds, and corporations in which the Company invests its surplus funds. The Company has experienced no credit losses from its cash and cash equivalent investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Maturity Of Time Deposits MaturityOfTimeDeposits	P1Y
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2981010	usd
CY2022Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	2870	usd
CY2022Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	2978140	usd
CY2020Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1007206	usd
CY2021	nmtc	Conversion Of Convertible Promissory Notes To Common Stock ConversionOfConvertiblePromissoryNotesToCommonStock	-1005232	usd
CY2021	nmtc	Change In Fair Value Including Accrued Interest ChangeInFairValueIncludingAccruedInterest	-1974	usd
CY2022	nmtc	Number Of Licencing Agreements NumberOfLicencingAgreements	2	pure
CY2021Q3	nmtc	Royalty Minimum Payments Year Two RoyaltyMinimumPaymentsYearTwo	100000	usd
CY2022Q3	nmtc	Royalty Minimum Payments Year Three RoyaltyMinimumPaymentsYearThree	150000	usd
CY2022	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	663629	usd
CY2021	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	80356	usd
CY2022	nmtc	Warrantshares Warrantshares	7103344	shares
CY2021	nmtc	Warrantshares Warrantshares	7503808	shares
CY2022	nmtc	Stock Options StockOptions	1239915	shares
CY2021	nmtc	Stock Options StockOptions	1122560	shares
CY2022	nmtc	Restricted Stock Unit RestrictedStockUnit	414430	shares
CY2021	nmtc	Restricted Stock Unit RestrictedStockUnit	11384	shares
CY2022	nmtc	Unissued Vested Restricted Stock Units UnissuedVestedRestrictedStockUnits	7316	shares
CY2021	nmtc	Unissued Vested Restricted Stock Units UnissuedVestedRestrictedStockUnits	1148	shares
CY2021Q3	nmtc	Inventory Finished Goods1 InventoryFinishedGoods1		usd
CY2022	nmtc	Lease Agreement Description LeaseAgreementDescription	The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term. In addition, as long as the Company is not in default under the Lease, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set forth in the Lease of which the Company is entitled to an abatement of these operating expense for the first 3 months.
CY2021Q3	nmtc	Lease Space LeaseSpace	1162	sqm
CY2021Q3	nmtc	Lease Rental Expense LeaseRentalExpense	4241	usd
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2022	nmtc	Monthly Lease Rent MonthlyLeaseRent	504	usd
CY2022	nmtc	Rent Expense RentExpense	170501	usd
CY2021	nmtc	Rent Expense RentExpense	136826	usd
CY2022	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	130727	usd
CY2021	nmtc	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	70897	usd
CY2021	nmtc	Operating Leases OperatingLeases	73118	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	181355	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	288948	usd
CY2022Q3	nmtc	Lease Liability LeaseLiability	202895	usd
CY2021Q3	nmtc	Lease Liability LeaseLiability	315673	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.069	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067	pure
CY2022Q3	nmtc	Lessee Operating Lease Liability Payments Due One Year LesseeOperatingLeaseLiabilityPaymentsDueOneYear	32928	usd
CY2022Q3	nmtc	Lessee Operating Lease Liability Payments Due Two Year LesseeOperatingLeaseLiabilityPaymentsDueTwoYear	82333	usd
CY2022Q3	nmtc	Lessee Operating Lease Liability Payments Due Three Year LesseeOperatingLeaseLiabilityPaymentsDueThreeYear	84391	usd
CY2022Q3	nmtc	Lessee Operating Lease Liability Payments Due Four Year LesseeOperatingLeaseLiabilityPaymentsDueFourYear	21227	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	220879	usd
CY2022Q3	nmtc	Imputed Interest ImputedInterest	-17984	usd
CY2022Q3	nmtc	Lease Liability Net LeaseLiabilityNet	202895	usd
CY2022Q3	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	83339	usd
CY2022Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	119556	usd
CY2022Q3	nmtc	Inventory Working Process InventoryWorkingProcess	630570	usd
CY2021Q3	nmtc	Inventory Working Process InventoryWorkingProcess	98287	usd
CY2022Q3	nmtc	Inventory Finished Goods1 InventoryFinishedGoods1	73968	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	704538	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	98287	usd
CY2022Q3	nmtc	Prepaid Expenses PrepaidExpenses	296649	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	521368	usd
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	376236	usd
CY2022Q3	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	83339	usd
CY2021Q3	nmtc	Prepaid Expenses PrepaidExpenses	151109	usd
CY2021Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	92934	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	296649	usd
CY2021Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	244043	usd
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	156523	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22316	usd
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	134207	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22315	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111892	usd
CY2022	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	22000	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	538061	usd
CY2021Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	311486	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1895	usd
CY2021Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1895	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	539956	usd
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	313381	usd
CY2022Q3	nmtc	Less Accumulated Depreciations LessAccumulatedDepreciations	-186357	usd
CY2021Q3	nmtc	Less Accumulated Depreciations LessAccumulatedDepreciations	-90052	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	353599	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	223329	usd
CY2022	us-gaap	Depreciation Depreciation	96305	usd
CY2021	us-gaap	Depreciation Depreciation	58432	usd
CY2021Q3	nmtc	Lease Liability Shortterms LeaseLiabilityShortterms	112778	usd
CY2022Q3	nmtc	Royalty Payments RoyaltyPayments	111132	usd
CY2021Q3	nmtc	Royalty Payments RoyaltyPayments	72083	usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	83152	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	715839	usd
CY2021Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	644249	usd
CY2022	nmtc	Paycheck Protection Program Description PaycheckProtectionProgramDescription	The PPP authorizes over $600 billion in forgivable loans to small businesses. Loan amounts may be forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent, and utility costs over a 24-week measurement period following loan funding. Loans have a maturity of 2 years and an interest rate of 1%. Prepayments may be made without penalty. In April 2020, the Company received loan funding of $83,333 under the PPP and was recorded as a long-term liability. The PPP loan was forgiven on June 9, 2021 by the U.S. Small Business Administration and was reflected as other income in the accompanying statements of operations. Interest was nominal during the year ended September 30, 2021.
CY2022	nmtc	Intial Fee Payment IntialFeePayment	2000000	usd
CY2022	nmtc	Aggregate Number Of Warrants Exercisable AggregateNumberOfWarrantsExercisable	350000	shares
CY2022Q3	us-gaap	Share Price SharePrice	3
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.029	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.535	pure
CY2022	nmtc	Expected Term ExpectedTerm	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Business Development BusinessDevelopment	5400000	usd
CY2022	nmtc	Initial Exclusivity Fee InitialExclusivityFee	2000000	usd
CY2022	nmtc	Under Payments UnderPayments	3500000	usd
CY2022	nmtc	Fair Value Of Warrants FairValueOfWarrants	100000	usd
CY2020Q3	us-gaap	Deferred Revenue DeferredRevenue	73434	usd
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	64812	usd
CY2021Q3	us-gaap	Deferred Revenue DeferredRevenue	8622	usd
CY2022	nmtc	Zimmer Agreement Amendment Related To Seeg Exclusivity Maintenance ZimmerAgreementAmendmentRelatedToSEEGExclusivityMaintenance	1455188	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	8622	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	1455188	usd
CY2022	us-gaap	Revenues Revenues	171169	usd
CY2021	us-gaap	Revenues Revenues	178146	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	270612	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	338837	usd
CY2021	nmtc	Changes Of Fair Value Benefit ChangesOfFairValueBenefit	-1974	usd
CY2021Q4	nmtc	Accrued And Unpaid Interest AccruedAndUnpaidInterest	615159	usd
CY2021Q4	nmtc	Shares Of Common Stock SharesOfCommonStock	292754	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	947212	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1793199	usd
CY2021	nmtc	Option Plan Increases For Future Award Issuances OptionPlanIncreasesForFutureAwardIssuances	0.13	pure
CY2021	nmtc	Stock Option Vested Over A Period Term StockOptionVestedOverAPeriodTerm	P10Y
CY2022	nmtc	Total Expense Of Stock Option TotalExpenseOfStockOption	582329	usd
CY2021	nmtc	Total Expense Of Stock Option TotalExpenseOfStockOption	983301	usd
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	492842	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.13
CY2021	nmtc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2020Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue1	96088	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	703117	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.83
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1538	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.6
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	71861	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.85
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1122560	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.89
CY2021	nmtc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	127339	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	152690	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	35335	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.14
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1239915	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.4
CY2022	nmtc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	89295	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1239915	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.4
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y
CY2022	nmtc	Sharebased Compensation Aggregate Intrinsic Value Vested And Exercisable At Ending SharebasedCompensationAggregateIntrinsicValueVestedAndExercisableAtEnding	89295	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	783494	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	5.76
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2022	nmtc	Aggregate Intrinsic Value Vestedandexercisable AggregateIntrinsicValueVestedandexercisable	56542	usd
CY2022	nmtc	Exercise Price Of Underlying Options ExercisePriceOfUnderlyingOptions	1.69
CY2021	nmtc	Exercise Price Of Underlying Options ExercisePriceOfUnderlyingOptions	3.95
CY2022Q3	nmtc	Outstanding Stock Options Shares OutstandingStockOptionsShares	1125710	shares
CY2021Q3	nmtc	Outstanding Stock Options Shares OutstandingStockOptionsShares	1055376	shares
CY2020Q3	nmtc	Weighted Average Exercise Price Outstanding And Exercisable Ending WeightedAverageExercisePriceOutstandingAndExercisableEnding	7.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y10M20D
CY2021	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod	4166682	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	443670	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	40624	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	414430	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	645910	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1700000	usd
CY2021	nmtc	Exercise Price Per Warrant Issued ExercisePricePerWarrantIssued	5.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.535	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.559	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.023	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006	pure
CY2022Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	327615	shares
CY2021Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	280557	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1538	shares
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	2648	usd
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	26698	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	13776	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	29090	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	11384	shares
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2021Q4	nmtc	Purchase Of Additional Shares PurchaseOfAdditionalShares	562500	shares
CY2022	nmtc	Total Gross Proceeds TotalGrossProceeds	13400000	usd
CY2022	nmtc	Other Offering Expenses Payable OtherOfferingExpensesPayable	1400000	usd
CY2020Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber	3390320	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.29
CY2021	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod	-53194	shares
CY2021	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1	5.61
CY2021Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber	7503808	shares
CY2021Q3	nmtc	Weighted Average Exercise Price Outstanding And Exercisable Ending WeightedAverageExercisePriceOutstandingAndExercisableEnding	6.06
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y2M23D
CY2022	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod	350000	shares
CY2022	nmtc	Exercise Price Per Warrant Issued ExercisePricePerWarrantIssued	3
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3
CY2022	nmtc	Weighted Average Termyears Issuedin Shares WeightedAverageTermyearsIssuedinShares	P4Y10M2D
CY2022	nmtc	Warrants Reverse Split Adjustment Correction WarrantsReverseSplitAdjustmentCorrection	-100	shares
CY2022	nmtc	Warrants Forfeitedin Shares WarrantsForfeitedinShares	-750364	shares
CY2022	nmtc	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited	5.4
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.4
CY2022	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsOutstanding	7103344	shares
CY2022	nmtc	Weighted Average Exercise Price Outstanding WeightedAverageExercisePriceOutstanding	5.98
CY2022	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerm	P2Y8M4D
CY2022Q3	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVvestedNumber	6753344	shares
CY2022Q3	nmtc	Weighted Average Exercise Price Outstanding And Exercisable Ending WeightedAverageExercisePriceOutstandingAndExercisableEnding	6.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y6M25D
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11918000	usd
CY2022Q3	nmtc	Income Tax Benefit At Federal Statutory Rate IncomeTaxBenefitAtFederalStatutoryRate	-0.21	pure
CY2021Q3	nmtc	Income Tax Benefit At Federal Statutory Rate IncomeTaxBenefitAtFederalStatutoryRate	-0.21	pure
CY2022Q3	nmtc	State Income Tax Net Of Federal Benefit StateIncomeTaxNetOfFederalBenefit	-0.077	pure
CY2021Q3	nmtc	State Income Tax Net Of Federal Benefit StateIncomeTaxNetOfFederalBenefit	-0.077	pure
CY2022Q3	nmtc	Research Credits ResearchCredits	-0.03	pure
CY2021Q3	nmtc	Research Credits ResearchCredits	-0.037	pure
CY2022Q3	nmtc	Stockbased Compensation StockbasedCompensation	0.007	pure
CY2021Q3	nmtc	Stockbased Compensation StockbasedCompensation	0.01	pure
CY2022Q3	nmtc	Valuation Allowance ValuationAllowance	0.31	pure
CY2021Q3	nmtc	Valuation Allowance ValuationAllowance	0.314	pure
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2022	nmtc	Proceeds From Issuance Of Warrants In Connection With Private Placement ProceedsFromIssuanceOfWarrantsInConnectionWithPrivatePlacement		usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	10164679	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	7575069	usd
CY2022Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	26447	usd
CY2021Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	24541	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	70399	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	8370	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1107559	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	812781	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	688998	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	451757	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12058082	usd
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8872518	usd
CY2022Q3	nmtc	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	140538	usd
CY2021Q3	nmtc	Deferred Tax Liabilities Fixed Assets And Other DeferredTaxLiabilitiesFixedAssetsAndOther	64189	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	140538	usd
CY2021Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	64189	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11917544	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8808329	usd
CY2022	nmtc	Deferred Tax Asset Gross Current DeferredTaxAssetGrossCurrent	12058000	usd
CY2021	nmtc	Deferred Tax Asset Gross Current DeferredTaxAssetGrossCurrent	8873000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8808000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	35408000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	26355000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	759000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	506000	usd
CY2022Q3	nmtc	Deferred Tax Asset Operating Loss Carryforwards State And Local DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal	35249000	usd
CY2021Q3	nmtc	Deferred Tax Asset Operating Loss Carryforwards State And Local DeferredTaxAssetOperatingLossCarryforwardsStateAndLocal	26355000	usd
CY2022Q3	nmtc	State Tax Credit Carry Forward StateTaxCreditCarryForward	441000	usd
CY2021Q3	nmtc	State Tax Credit Carry Forward StateTaxCreditCarryForward	307000	usd
CY2022	nmtc	Issuance Costs In Connection With Convertible Promissory Notes IssuanceCostsInConnectionWithConvertiblePromissoryNotes		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	nmtc	Deferreds Offering Costs DeferredsOfferingCosts		usd
CY2022	nmtc	Conversion Of Convertible Promissory Notes To Equity ConversionOfConvertiblePromissoryNotesToEquity		usd
CY2022	nmtc	Broker Warrants Issued In Connection With Convertible Notes BrokerWarrantsIssuedInConnectionWithConvertibleNotes		usd
CY2022	nmtc	Operating Lease Right Of Use Asset Obtained In Exchange For Operating Lease OperatingLeaseRightOfUseAssetObtainedInExchangeForOperatingLease		usd
CY2022	nmtc	Value Of Payroll Protection Program Loan Forgiveness ValueOfPayrollProtectionProgramLoanForgiveness		usd
CY2022	nmtc	Employees Compensation Percentage EmployeesCompensationPercentage	1	pure
CY2022	nmtc	Deferrals Percentage DeferralsPercentage	1	pure
CY2022	nmtc	Contributions Percentage ContributionsPercentage	0.03	pure
CY2022	nmtc	Internal Revenue Percentage InternalRevenuePercentage	1	pure
CY2022	nmtc	Contributions Amount ContributionsAmount	30697	usd
CY2021	nmtc	Contributions Amount ContributionsAmount	14803	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent		usd
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2021	nmtc	Sharebased Compensation Aggregate Intrinsic Value Granted SharebasedCompensationAggregateIntrinsicValueGranted		usd
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
CY2021	nmtc	Sharebased Compensation Aggregate Intrinsic Value Exercised SharebasedCompensationAggregateIntrinsicValueExercised		usd
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2021	nmtc	Sharebased Compensation Aggregate Intrinsic Value Forfeited Cancelled SharebasedCompensationAggregateIntrinsicValueForfeitedCancelled		usd
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2022	nmtc	Sharebased Compensation Aggregate Intrinsic Value Granted SharebasedCompensationAggregateIntrinsicValueGranted		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
CY2022	nmtc	Sharebased Compensation Aggregate Intrinsic Value Exercised SharebasedCompensationAggregateIntrinsicValueExercised		usd
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
CY2022	nmtc	Sharebased Compensation Aggregate Intrinsic Value Forfeited Cancelled SharebasedCompensationAggregateIntrinsicValueForfeitedCancelled		usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1		usd
CY2021	nmtc	Weighted Average Termyears Issuedin Shares WeightedAverageTermyearsIssuedinShares
CY2021	nmtc	Warrants Forfeitedin Shares WarrantsForfeitedinShares		shares
CY2021	nmtc	Weighted Average Exercise Price Forfeited WeightedAverageExercisePriceForfeited
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021	nmtc	Weighted Average Termyears Forfeitedin Shares WeightedAverageTermyearsForfeitedinShares
CY2022	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod		shares
CY2022	nmtc	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised
CY2022	nmtc	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1
CY2022	nmtc	Weighted Average Termyears Exercisedin Shares WeightedAverageTermyearsExercisedinShares
CY2022	nmtc	Exercise Price Per Warrant Reverse Split Adjustment Correction ExercisePricePerWarrantReverseSplitAdjustmentCorrection
CY2022	nmtc	Weighted Average Exercise Price Reverse Split Adjustment Correction WeightedAverageExercisePriceReverseSplitAdjustmentCorrection
CY2022	nmtc	Weighted Average Termyears Reverse Split Adjustment Correctionin Dollars WeightedAverageTermyearsReverseSplitAdjustmentCorrectioninDollars
CY2022	nmtc	Weighted Average Termyears Forfeitedin Shares WeightedAverageTermyearsForfeitedinShares
CY2022Q3	nmtc	Effective Tax Rate EffectiveTaxRate		pure
CY2021Q3	nmtc	Effective Tax Rate EffectiveTaxRate		pure
CY2022Q3	nmtc	Deferred Income Tax Asset Net DeferredIncomeTaxAssetNet		usd
CY2021Q3	nmtc	Deferred Income Tax Asset Net DeferredIncomeTaxAssetNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001500198

Files In Submission

Name	View Source	Status
0001213900-22-081897-index-headers.html	Edgar Link	pending
0001213900-22-081897-index.html	Edgar Link	pending
0001213900-22-081897.txt	Edgar Link	pending
0001213900-22-081897-xbrl.zip	Edgar Link	pending
ex5-1_001.jpg	Edgar Link	pending
f10k2022ex1-1_neuroone.htm	Edgar Link	pending
f10k2022ex21-1_neuroone.htm	Edgar Link	pending
f10k2022ex23-1_neuroone.htm	Edgar Link	pending
f10k2022ex31-1_neuroone.htm	Edgar Link	pending
f10k2022ex31-2_neuroone.htm	Edgar Link	pending
f10k2022ex32-1_neuroone.htm	Edgar Link	pending
f10k2022ex32-2_neuroone.htm	Edgar Link	pending
f10k2022ex5-1_neuroone.htm	Edgar Link	pending
f10k2022_neuroone.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmtc-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmtc-20220930_def.xml	Edgar Link	unprocessable
nmtc-20220930_pre.xml	Edgar Link	unprocessable
nmtc-20220930_lab.xml	Edgar Link	unprocessable
f10k2022_neuroone_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nmtc-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2022 Q4 Form 10-K Financial Statement

#000121390022081897 Filed on December 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc

2022 Q4 Form 10-K Financial Statement

#000121390022081897 Filed on December 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp Stock $nmtc